Reminder - Nuveen California Dividend Advantage Municipal Fund (NAC) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 5/13/13, Nuveen California Dividend Advantage Municipal Fund (NAC) will trade ex-dividend, for its monthly dividend of $0.074, payable on 6/3/13. As a percentage of NAC's recent stock price of $15.46, this dividend works out to approximately 0.48%.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for NAC, showing historical dividends prior to the most recent $0.074 declared by Nuveen California Dividend Advantage Municipal Fund:

NAC+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from NAC is likely to continue, and whether the current estimated yield of 5.74% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of NAC shares, versus its 200 day moving average:

Nuveen California Dividend Advantage Municipal Fund 200 Day Moving Average Chart

Looking at the chart above, NAC's low point in its 52 week range is $14.55 per share, with $16.58 as the 52 week high point — that compares with a last trade of $15.46.

In Thursday trading, Nuveen California Dividend Advantage Municipal Fund shares are currently down about 0.3% on the day.

null

More from Stocks

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Spotify Announces Major Upgrade to Free Mobile App

Spotify Announces Major Upgrade to Free Mobile App

Looks like Coca-Cola's M&A Strategy Is Paying Off

Looks like Coca-Cola's M&A Strategy Is Paying Off

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug